menu menu_open
Brasil
home Sumário navigate_before Anterior Atual Seguinte navigate_next
home Sumário
Review • Adv. rheumatol. 64 • 2024 • https://doi.org/10.1186/s42358-024-00373-z linkcopy

Open-access Unraveling the genetic collagen connection: clinical and therapeutic insights on genetic connective tissue disorders

AuthorshipSCIMAGO INSTITUTIONS RANKINGS

    Abstract

    Hereditary connective tissue disorders include more than 200 conditions affecting different organs and tissues, compromising the biological role of the extracellular matrix through interference in the synthesis, development, or secretion of collagen and/or its associated proteins. The clinical phenotype includes multiple signs and symptoms, usually nonspecific but of interest to rheumatologists because of musculoskeletal involvement. The patient's journey to diagnosis is long, and physicians should include these disorders in their differential diagnoses of diseases with systemic involvement. In this review, insights for the diagnosis and treatment of osteogenesis imperfecta, hypermobility spectrum disorder/Ehlers–Danlos syndrome, Marfan, Loeys–Dietz, and Stickler syndromes are presented.

    Keywords Collagen; Extracellular matrix; Connective tissue disease; Osteogenesis imperfecta; Ehlers–Danlos syndrome; Marfan syndrome; Loeys–Dietz syndrome; Stickler syndrome

    Introduction

    Hereditary connective tissue disorders (HCTD) may arise from defects in the biosynthesis, assembly, post-translational modification, secretion, or other processes involved in normal collagen formation, including enzymes and accessory proteins (for example, fibrillin, for which pathogenic variants cause Marfan syndrome – MFS) [1-3].

    There are more than 200 conditions that may be characterized as HCTD. These disorders comprise a complex group of generally low-prevalence diseases that manifest variable clinical signs and symptoms and can be encountered in different specialties, such as rheumatology, orthopedics, nephrology, ophthalmology, dermatology, angiology, and gastroenterology. Furthermore, genetic characteristics such as pleiotropism and variable expressivity, in addition to epigenetic and environmental factors, contribute to increasing not only the diagnostic but also the therapeutic challenge [2, 4].

    Often, these conditions involve overlapping symptoms and treatments, and physicians should be able to recognize patients with personal and/or family history of one or more of these conditions: joint or spine deformity (e.g. scoliosis, spondylolisthesis), joint hypermobility or deformity (e.g. plain pes planus), unusually short or tall stature, skin hyperextensibility, tissue fragility, poor wound healing, easy bruising, arterial dilatation or dissection, intestinal or uterine spontaneous rupture, unexplained organ infarction, multiple fractures from minor or no trauma, lens dislocation, abnormality of the cornea, spontaneous pneumothorax, or hearing loss [2].

    The extracellular matrix

    The extracellular matrix is a dynamic structure composed of a mixture of water and collagens, proteoglycans, elastic proteins, and noncollagenous glycoproteins. The composition of organs and tissues differs, and organs and tissues are adjusted to meet the biological requirements of each organ (flexibility, resistance, structural framework).

    Collagens are protein molecules composed of amino acids that follow a predefined sequence and are characterized by the formation of trimers (three chains), which are later organized into fibers. They are abundant in organisms, particularly in the extracellular matrix, and are also essential for homeostasis, morphogenesis, and tissue differentiation [3, 5-7].

    The collagen synthesis process occurs in fibroblasts via intracellular (messenger RNA transcription, translation, and posttranslational modification) and extracellular (propeptide cleavage and collagen fibril assembly) steps. The primary amino acid sequence of collagen is glycine-proline-X, or glycine-X-hydroxyproline, among which X can be any of the other amino acids, and every third amino acid is glycine (the smallest amino acid). The presence of a glycine at every third position is essential for the formation of the triple helix, which is located at the center of the molecule [3, 5].

    There are currently 28 distinct types of collagens, of which I to V are the most prevalent. Interestingly, 90% of the collagen in the human body is type I and can be found in the skin, tendons, vessels, bones, and internal organs. Type II collagen is the main component of cartilage, and type III collagen is the main component of reticular fibers and occurs in smooth muscle, the endoneurium and the trabeculae of hematopoietic organs. Type IV collagen comprises the basal lamina, and type V collagen is found in the placenta, hair, and cell surfaces [3, 5].

    Most dominant negative variants in collagen genes are caused by the substitution of one of the glycines in the collagenous domains of the α chains by a larger amino acid. These glycine substitutions may cause diseases with different phenotypes, from osteogenesis imperfecta (OI) and subtypes of Ehlers–Danlos syndrome (EDS) to chondrodysplasia and Alport syndrome [3]. Table 1 lists specific collagen diseases that can present with musculoskeletal issues and may require rheumatologic and/or orthopedic evaluation.

    Thumbnail
    Table 1
    Hereditary collagen-related disorders with signs and/or symptoms that may prompt rheumatologic and/or orthopedic consultation

    This Review delves into clinical and therapeutic aspects of hereditary connective tissue disorders of most interest for those involved in the care of patients with systemic diseases and incorporates the new nomenclature following the 2023 Nosology of Skeletal Dysplasias publication [8]. The main focus of the manuscript is about establishing a clinical suspicion. Additional investigation, including genetic testing, may be ordered to each disease. It is important for non-specialists to understand that not all patients will have a positive genetic test, and that a negative genetic test does not exclude the possibility of the disease. With this rationale, ordering genetic testing should be reserved to physicians experienced with the different tests and their appropriate interpretation. Genetic counseling is always required in the setting of these rare diseases.

    Osteogenesis imperfecta

    Osteogenesis imperfecta is characterized by impaired bone formation and strength, leading to bone fragility. It occurs worldwide and affects all races and ethnicities. Its prevalence ranges from 1 in 10,000 to 1 in 20,000 live births. The disease has a variable course, ranging from mild to severe and lethal. Clinical manifestations include bone fragility, with bone fractures secondary to mild trauma or even spontaneously; short stature; bone deformities, that contribute to impaired walking, thoracic restriction, and dyspnea; brittle teeth; impaired hearing; and joint hyperextensibility [9, 10]. Blue sclerae may be seen in OI but also in Hypermobility Spectrum Disorders/EDS and Marfan syndrome. Additionally, other diseases not comprising collagen and collagen-related genetic diseases may present with blue sclerae, such as iron deficiency or drug toxicity.

    Ancillary exams are not specific. Imaging, for example radiography and bone densitometry, is important for fracture diagnosis and follow-up. Genetic testing should be sought for specific diagnosis and counseling, as inheritance patterns may be autosomal dominant, autosomal recessive or X-linked [10]. Table 2 shows the most up-to-date classification [8], in which OI is divided into 4 different phenotypes (non-deforming, moderate, progressively deforming, and severe perinatal forms), consistent with the original phenotypic classification by Sillence et al. [11], and combining the new genetic data with previous expanded Sillence classification (from I to XXIII), with descriptors and Online Mendelian Inheritance in Man (OMIM) numbers [12].

    Thumbnail
    Table 2
    Classification of Osteogenesis Imperfecta According to the 2023 Skeletal Dysplasia Nosology [8]

    Patients with OI require interdisciplinary and personalized treatment comprising both clinical and surgical approaches. Supportive clinical treatment includes dental care, audiological care, rehabilitation, physical therapy, pain modulation, and bone-targeted drugs, such as bisphosphonates, to increase bone mineral density and reduce fracture risk, although not conclusively. There is currently no compelling evidence to support the use of teriparatide in the treatment of osteogenesis imperfecta. Improvement in bone mineral density is apparent, but this observation was limited to patients with OI type I. Protocols with romosozumab in humans with OI are lacking but a different sclerostin inhibitor is currently being studied in these patients – sestrusumab. Devices to assist mobility and prevent falls may be needed. Surgical procedures are directed at improvement of patient growth and development, correction and/or prevention of deformities and enhancement of quality of life. Surgical interventions include intramedullary rod placement, surgery to manage basilar invagination, and correction of scoliosis [9, 13, 14].

    The prognosis for OI varies in accordance with the severity of the disease and the response to treatment. Patients may lead active, productive lives with appropriate treatment. However, in severe cases, bone fragility can significantly impose limitations on daily living activities and cause complications [9]. Importantly, physicians caring for these patients must include as differential other genetic diseases, such as hypophosphatasia, and child maltreatment.

    Hypermobility spectrum disorder/Ehlers-Danlos syndrome

    Hypermobility spectrum disorders (HSD) are connective tissue disorders that cause joint hypermobility, instability, injury, and recurrent, persistent, and/or chronic pain. HSD is diagnosed by medical history and physical examination, and this terminology should not be used for asymptomatic persons. Physicians should inquire about their history of joint luxation and/or subluxation, early cartilage lesions or evidence of early-onset osteoarthritis and recurrent soft tissue lesions (sprains, tendinopathies) in addition to chronic pain. Physical examination should encompass assessment of proprioception and the use of the Beighton [15] criteria, assuming age and sex influences, to help establish a clinical diagnosis. Notably, hypermobile joints may not always have a specific relationship with collagen disorders since they can be identified in distinct genetic disorders, for example: Down syndrome (trisomy 21), homocystinuria (cystathionine β-synthase deficiency) and mucopolyssacaridosis type VI (lysosomal hydrolase N-acetylgalactosamine 4-sulfatase deficiency) [16-18].

    Some patients may definitely have Ehlers–Danlos syndrome, corroborating the updated language that considers HSD and EDS a continuum [19]. EDS is a rare condition with different prevalence according to subtypes that comprise 13 different phenotypes, each with distinct diagnostic criteria. It is estimated to affect 1 in 5,000 people worldwide. The most common subtype is hypermobile EDS, which lacks association with a specific gene. In addition to musculoskeletal signs and symptoms, the clinical manifestations of EDS can vary significantly between subtypes and include skin hyperextensibility, easy bruising, and abnormal scarring; moreover, some patients may experience viscus rupture, spontaneous arterial dissection, or aneurysm formation. The clinical circular (not linear) continuum also includes aspects such as fatigue, headache, anxiety, gastrointestinal problems, mast cell activation disorder, and autonomic dysfunction [17, 18, 20].

    Like OI, HSD/EDS is diagnosed on clinical grounds, and supplementary exams are not specific. Imaging studies will evaluate musculoskeletal manifestations such as osteoarthritis, scoliosis, cervical instability, normal or decreased bone density, and heart and vascular disorders, that is heart valve disease, rhythm disturbances, autonomic disorders, arterial enlargement, and dissection [9, 20]. Genetic studies may identify a background that enables counseling. Table 3 depicts the 2017 nomenclature and genes associated with EDS [17]. Interestingly, spondylodysplastic and musculocontractural EDS are also considered at the 2023 Skeletal Dysplasia Nosology [8]; and periodontal EDS, is contemplated at the 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee [21].

    Thumbnail
    Table 3
    Classification of Ehlers–Danlos Syndrome [16]

    HSD/EDS treatment is aimed at symptom relief, damage prevention, and quality of life improvement. These interventions may include rehabilitation, physical and occupational therapies, analgesics, pain modulators and short courses of nonsteroidal anti-inflammatory drugs to relieve pain. Beta blockers are recommended for patients with vascular EDS to prevent arterial enlargement and may be indicated for dysautonomia as an option for postural orthostatic tachycardia syndrome. Surgery is reserved for severe dislocations and vascular or internal organ complications. Psychological care plays a significant role in these patients [18, 20, 22].

    The prognosis varies with the severity of the disease and the impact of the manifestations on daily and professional activities [20].

    Marfan syndrome

    Marfan syndrome (NOS 31-0010) is a type 1 fibrillinopathy caused by pathogenic variants in FBN1 gene, which encodes fibrillin-1. Not all type 1 fibrillinopathies manifest marfanoid features. The fibrillin-1 protein is important for the extracellular matrix underlying arteries, pericondrium and eye structures. The disease can occur de novo in 25% of the patients or be inherited in an autosomal dominant pattern. The prevalence of the carrying status of FBN1 is estimated to be 6.5 cases per 100,000 persons [23-26].

    Clinical signs and symptoms include aortic root aneurysm, aortic dissection, ectopia lentis, and skeletal abnormalities/marfanoid habitus, inclusive of high stature, disproportionally long limbs (arm span-to-height ratio > 1.05), pectus excavatum or carinatum, arachnodactyly, and scoliosis [27]. The revised Ghent diagnostic criteria aid in the identification of these patients. Table 4 shows the MFS diagnostic criteria [26].

    Thumbnail
    Table 4
    Revised Ghent Diagnostic Criteria for Marfan Syndrome [26]

    Adequate diagnosis and prophylactic usage of β-blockers can prevent aneurysm enlargement and aortic dissection. Angiotensin-II receptor blockers, either alone or in combination with β-blockers, also play a role in the prevention of aortic growth in patients with MFS. Regular imaging and lifestyle modifications are the first steps for the protection of the aorta. Ophthalmological care is warranted. Prevention of additional cardiovascular risk factors should be encouraged. Elective surgery is indicated in the case of aortic root dilatation of ≥ 5 mm/year or an absolute aortic diameter of ≥ 50 mm at any level. Surgical stabilization of the spinal deformity should be considered when the curve progresses beyond 40 degrees. Retinal detachment needs to be diagnosed early and can be managed with laser surgery, vitrectomy, or scleral buckle surgery according to the surgeon's indications. If the lens is dislocated to the extent that the patient's vision cannot be corrected through the lens, the risk, benefit, and timing of removal of the dislocated lens must be carefully considered. Bone density should be assessed but it is infrequently a significant issue [22, 24, 27, 28].

    Loeys–Dietz syndrome

    Loeys–Dietz syndrome (LDS) is a TGFβ signaling pathway condition that affects multiple organ systems and comprises different subtypes, all of which exhibit autosomal dominant inheritance (Table 5). This syndrome is an important differential syndrome for patients with a Marfan-like phenotype not fulfilling the MFS diagnostic criteria, usually with aortic and skeletal features but without ectopia lentis, and for patients reminiscent of vascular EDS, with negative COL3A1 genetic testing. The risk for arterial dissection in these patients may be greater than that in patients with MFS, and arterial dissection may occur at a younger age [22, 29-31].

    Thumbnail
    Table 5
    Classification of Loeys–Dietz syndrome

    LDS1 (TGFBR1-related) is characterized by arterial tortuosity and/or aneurysms, most frequently of the aorta, combined with craniofacial abnormalities, including hypertelorism, bifid uvula or cleft palate. Arachnodactyly, pectus deformity, retrognathia, and joint laxity may be additional clinical features. LDS2 (TGFBR2‐related) is characterized by arterial tortuosity, aortic aneurysms, hypertelorism, abnormal uvula, joint laxity, pectus deformity, scoliosis, arachnodactyly, and malar hypoplasia. Notably, LDS2 is characterized by minimal craniofacial abnormalities compared to LDS1 [29, 30].

    LDS3 (SMAD3-related) is characterized by early-onset osteoarthritis and osteochondritis dissecans. Additionally, patients may exhibit scoliosis, aortic aneurysms, cerebral arterial tortuosity, mitral valve prolapse, and abnormal uvula and palate. Most patients develop osteoarthritis by the fourth decade of life, with frequent involvement of the hands, wrists, knees, and cervical and lumbar spine, with intervertebral disc degeneration [29, 30].

    LDS4 (TGFB2-related) patients may present with aortic aneurysms and dissection, joint laxity, pectus deformities, scoliosis, arachnodactyly, pes planus, high-arched palate, or umbilical/inguinal hernias. The few patients diagnosed with LDS5 (TGFB3‐related) were described as having aortic aneurysms with a risk of dissection, arachnodactyly, pectus deformity, pes planus or clubfeet, hypertelorism, abnormal uvula, joint laxity, cervical spine instability and skeletal overgrowth [29, 30].

    LDS6 (SMAD2-related) was described more recently in 4 patients from 3 unrelated families. Clinical signs and symptoms included aortic, carotid, and cerebral artery aneurysms; dysmorphic features; and skeletal and skin abnormalities [30].

    Early diagnosis warrants medical therapy and vascular surgery procedures to prevent arterial enlargement and dissection and orthopedic care to correct skeletal deformities [22]. Physical and occupational therapies aid in the supportive management of these patients. Low bone density with a propensity for fractures may be observed in all LDS variants, and specific therapy may be necessary [28].

    Stickler syndrome

    Stickler syndrome (STL) is a condition with a heterogeneous clinical presentation and genetic background characterized by ocular, auditory, skeletal, and orofacial manifestations [32]. Patients exhibit both autosomal dominant (STL1, COL11A1-related; and STL2, COL11A2-related; and COL11A2-related non-ocular type) [33] and autosomal recessive (STL4, COL9A1-related; and STL5, COL9A2-related; and STL6, COL9A3-related) [34] inheritance (Table 1). STL3 was reclassified as otospondylomegaepiphyseal dysplasia, COL11A2-related, and both types of autosomal inheritance were detected [8].

    Patients with most forms of STL exhibit ocular changes, including high myopia, vitreoretinal degeneration, and cataracts. Notably, it is the most common cause of retinal detachment in children and the most common cause of familial or inherited retinal detachment. These patients may also present cleft palate, bifid uvula, Pierre Robin sequence (micrognathia, glossoptosis, and airway obstruction), flat midface, and hearing impairment. Multiple epiphyseal dysplasias and early-onset osteoarthritis are common musculoskeletal features [32, 35].

    Treatment includes assessment by a craniofacial specialist and/or otolaryngologist, an ophthalmologist, a feeding specialist, and physical and occupational therapies. Preventative surgery is effective at prevention of retinal detachment in patients at substantial risk [32, 36].

    Conclusion

    Hereditary connective tissue disorders may be rare but can be recognized whenever physicians, particularly rheumatologists, consider the combination of signs and symptoms that, despite arising from different organs and tissues, can have a parallel genetic background. A multidisciplinary and multispecialty approach is fundamental for the adequate care of these patients. Knowledge of basic genetic concepts is important for nonspecialists to aid in the curtailment of the patients’ journeys and the reduction of misdiagnosis.

    • Funding
      Not applicable.
    • Declarations
      Ethics approval and consent to participate
      Not applicable.
    • Consent for publication
      All authors are aware of the full content of the manuscript and have consented for publication.
    • Publisher's Note
      Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    Data availability

    Data sharing not applicable – no new data generated.

    References

    • 1 Trackman PC. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem. 2005;96(5):927–37. https://doi.org/10.1002/jcb.20605
      » https://doi.org/10.1002/jcb.20605
    • 2 Medicine Division; Board on Health Care Services; Committee on Selected heritable disorders of connective tissue and disability, Health M. In: Wedge RA, Cartaxo T, Spicer CM, Volberding PA, editors. Selected heritable disorders of connective tissue and disability. Washington (DC): National Academies Press (US); 2022. p. 36223440.
    • 3 Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011;3(1):a004978. https://doi.org/10.1101/cshperspect.a004978
      » https://doi.org/10.1101/cshperspect.a004978
    • 4 Arseni L, Lombardi A, Orioli D. From structure to phenotype: impact of collagen alterations on Human Health. Int J Mol Sci. 2018;19(5):1407. https://doi.org/10.3390/ijms19051407
      » https://doi.org/10.3390/ijms19051407
    • 5 Sophia Fox AJ, Bedi A, Rodeo SA. The Basic Science of articular cartilage: structure, composition, and function. Sports Health. 2009;1(6):461–8. https://doi.org/10.1177/1941738109350438
      » https://doi.org/10.1177/1941738109350438
    • 6 Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(Pt 24):4195–200. https://doi.org/10.1242/jcs.023820
      » https://doi.org/10.1242/jcs.023820
    • 7 Yue B. Biology of the extracellular matrix: an overview. J Glaucoma. 2014;23(8 Suppl 1):S20–3. https://doi.org/10.1097/IJG.0000000000000108
      » https://doi.org/10.1097/IJG.0000000000000108
    • 8 Unger S, Ferreira CR, Mortier GR, Ali H, Bertola DR, Calder A, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164–209. https://doi.org/10.1002/ajmg.a.63132
      » https://doi.org/10.1002/ajmg.a.63132
    • 9 Charoenngam N, Nasr A, Shirvani A, Holick MF. Hereditary Metabolic Bone diseases: a review of Pathogenesis, diagnosis and management. Genes (Basel). 2022;13(10):1880. https://doi.org/10.3390/genes13101880
      » https://doi.org/10.3390/genes13101880
    • 10 Yu H, Li C, Wu H, Xia W, Wang Y, Zhao J, et al. Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification. Orphanet J Rare Dis. 2023;18(1):234. https://doi.org/10.1186/s13023-023-02849-5
      » https://doi.org/10.1186/s13023-023-02849-5
    • 11 Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
    • 12 Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), {Accessed December 10th, 2023}. https://omim.org/
      » https://omim.org/
    • 13 Botor M, Fus-Kujawa A, Uroczynska M, Stepien KL, Galicka A, Gawron K, et al. Osteogenesis Imperfecta: current and prospective therapies. Biomolecules. 2021;11(10):1493. https://doi.org/10.3390/biom11101493
      » https://doi.org/10.3390/biom11101493
    • 14 Liu W, Lee B, Nagamani SCS, Nicol L, Rauch F, Rush ET, et al. Approach to the patient: pharmacological therapies for fracture risk reduction in adults with Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023;108(7):1787–96.
    • 15 Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis. 1973;32(5):413–8. https://doi.org/10.1136/ard.32.5.413
      » https://doi.org/10.1136/ard.32.5.413
    • 16 Carroll MB. Hypermobility spectrum disorders: a review. Rheumatol Immunol Res. 2023;4(2):60–8. https://doi.org/10.2478/rir-2023-0010
      » https://doi.org/10.2478/rir-2023-0010
    • 17 Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification ofthe Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. https://doi.org/10.1002/ajmg.c.31552
      » https://doi.org/10.1002/ajmg.c.31552
    • 18 Malfait F, Castori M, Francomano CA, Giunta C, Kosho T, Byers PH. The Ehlers- Danlos syndromes. Nat Rev Dis Primers. 2020;6(1):64. https://doi.org/10.1038/s41572-020-0194-9
      » https://doi.org/10.1038/s41572-020-0194-9
    • 19 Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification ofjoint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148–57. https://doi.org/10.1002/ajmg.c.31539
      » https://doi.org/10.1002/ajmg.c.31539
    • 20 Miklovic T, Sieg VC, Ehlers-Danlos S. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.
    • 21 Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507. https://doi.org/10.1007/s10875-022-01289-3
      » https://doi.org/10.1007/s10875-022-01289-3
    • 22 Asta L, D’Angelo GA, Marinelli D, Benedetto U. Genetic basis, New Diagnostic approaches, and updated therapeutic strategies of the Syndromic Aortic diseases: Marfan, Loeys-Dietz, and Vascular Ehlers-Danlos Syndrome. Int J Environ Res Public Health. 2023;20(16):6615. https://doi.org/10.3390/ijerph20166615
      » https://doi.org/10.3390/ijerph20166615
    • 23 Sakai LY, Keene DR, Renard M, De Backer J. FBN1: the disease-causing gene for Marfan syndrome and other genetic disorders. Gene. 2016;591(1):279–91. https://doi.org/10.1016/j.gene.2016.07.033
      » https://doi.org/10.1016/j.gene.2016.07.033
    • 24 Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7(1):64. https://doi.org/10.1038/s41572-021-00298-7 Erratum in: Nat Rev Dis Primers. 2022;8(1):3.
      » https://doi.org/10.1038/s41572-021-00298-7
    • 25 Zeigler SM, Sloan B, Jones JA. Pathophysiology and Pathogenesis of Marfan Syndrome. Adv Exp Med Biol. 2021;1348:185–206. https://doi.org/10.1007/978-3-030-80614-9_8
      » https://doi.org/10.1007/978-3-030-80614-9_8
    • 26 Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–85. https://doi.org/10.1136/jmg.2009.072785
      » https://doi.org/10.1136/jmg.2009.072785
    • 27 Pollock L, Ridout A, Teh J, Nnadi C, Stavroulias D, Pitcher A, et al. The Musculoskeletal manifestations of Marfan Syndrome: diagnosis, impact, and management. Curr Rheumatol Rep. 2021;23(11):81. https://doi.org/10.1007/s11926-021-01045-3
      » https://doi.org/10.1007/s11926-021-01045-3
    • 28 Charoenngam N, Rittiphairoj T, Ponvilawan B, Jaroenlapnopparat A, Waitay- angkoon P, Suppakitjanusant P, et al. Bone fragility in Hereditary Connective tissue disorders: a systematic review and Meta-analysis. Endocr Pract. 2023;29(7):589–600. https://doi.org/10.1016/j.eprac.2023.02.003
      » https://doi.org/10.1016/j.eprac.2023.02.003
    • 29 Loeys BL, Dietz HC, Loeys-Dietz S. 2008 Feb 28 [updated 2018 Mar 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
    • 30 Camerota L, Ritelli M, Wischmeijer A, Majore S, Cinquina V, Fortugno P, et al. Genotypic categorization of Loeys-Dietz Syndrome based on 24 Novel Families and Literature Data. Genes (Basel). 2019;10(10):764. https://doi.org/10.3390/genes10100764
      » https://doi.org/10.3390/genes10100764
    • 31 Gouda P, Kay R, Habib M, Aziz A, Aziza E, Welsh R. Clinical features, and complications of Loeys-Dietz syndrome: a systematic review. Int J Cardiol. 2022;362:158–67. https://doi.org/10.1016/j.ijcard.2022.05.065
      » https://doi.org/10.1016/j.ijcard.2022.05.065
    • 32 Mortier G, Stickler Syndrome. 2000 Jun 9 [updated 2023 Sep 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
    • 33 Soh Z, Richards AJ, McNinch A, Alexander P, Martin H, Snead MP. Dominant Stickler Syndrome Genes (Basel). 2022;13(6):1089. https://doi.org/10.3390/genes13061089
      » https://doi.org/10.3390/genes13061089
    • 34 Nixon TRW, Richards AJ, Martin H, Alexander P, Snead MP. Autosomal recessive stickler syndrome. Genes (Basel). 2022;13(7):1135. https://doi.org/10.3390/genes13071135
      » https://doi.org/10.3390/genes13071135
    • 35 Boothe M, Morris R, Robin N. Stickler syndrome: a review of clinical manifestations and the Genetics evaluation. J Pers Med. 2020;10(3):105. https://doi.org/10.3390/jpm10030105
      » https://doi.org/10.3390/jpm10030105
    • 36 Snead M, Martin H, Bale P, Shenker N, Baguley D, Alexander P, et al. Therapeutic and diagnostic advances in Stickler syndrome. Ther Adv Rare Dis. 2020;1:2633004020978661. https://doi.org/10.1177/2633004020978661
      » https://doi.org/10.1177/2633004020978661

    Publication Dates

    • Publication in this collection
      12 Aug 2024
    • Date of issue
      2024

    History

    • Received
      05 Jan 2024
    • Accepted
      19 Apr 2024
    • Published
      25 Apr 2024
    Creative Common - by 4.0
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    vertical_align_top file_download show_chart
    location_on
    Sociedade Brasileira de Reumatologia Av. Brigadeiro Luís Antônio, 2466, Jardim Paulista, 01402-000 - São Paulo, SP, Tel.: +551132897165 - São Paulo - SP - Brazil
    E-mail: rbreumatol@terra.com.br
    rss_feed Acompanhe os números deste periódico no seu leitor de RSS
    Acessibilidade / Reportar erro